Home > Research > Publications & Outputs > Unmet need for COVID-19 vaccination coverage in...

Links

Text available via DOI:

View graph of relations

Unmet need for COVID-19 vaccination coverage in Kenya

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Unmet need for COVID-19 vaccination coverage in Kenya. / Muchiri, S.K.; Muthee, R.; Kiarie, H. et al.
In: Vaccine, Vol. 40, No. 13, 18.03.2022, p. 2011-2019.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Muchiri, SK, Muthee, R, Kiarie, H, Sitienei, J, Agweyu, A, Atkinson, PM, Edson Utazi, C, Tatem, AJ & Alegana, VA 2022, 'Unmet need for COVID-19 vaccination coverage in Kenya', Vaccine, vol. 40, no. 13, pp. 2011-2019. https://doi.org/10.1016/j.vaccine.2022.02.035

APA

Muchiri, S. K., Muthee, R., Kiarie, H., Sitienei, J., Agweyu, A., Atkinson, P. M., Edson Utazi, C., Tatem, A. J., & Alegana, V. A. (2022). Unmet need for COVID-19 vaccination coverage in Kenya. Vaccine, 40(13), 2011-2019. https://doi.org/10.1016/j.vaccine.2022.02.035

Vancouver

Muchiri SK, Muthee R, Kiarie H, Sitienei J, Agweyu A, Atkinson PM et al. Unmet need for COVID-19 vaccination coverage in Kenya. Vaccine. 2022 Mar 18;40(13):2011-2019. Epub 2022 Feb 14. doi: 10.1016/j.vaccine.2022.02.035

Author

Muchiri, S.K. ; Muthee, R. ; Kiarie, H. et al. / Unmet need for COVID-19 vaccination coverage in Kenya. In: Vaccine. 2022 ; Vol. 40, No. 13. pp. 2011-2019.

Bibtex

@article{3a0bf50a8ea54744850ed3dc1aed1ddd,
title = "Unmet need for COVID-19 vaccination coverage in Kenya",
abstract = "COVID-19 has impacted the health and livelihoods of billions of people since it emerged in 2019. Vaccination for COVID-19 is a critical intervention that is being rolled out globally to end the pandemic. Understanding the spatial inequalities in vaccination coverage and access to vaccination centres is important for planning this intervention nationally. Here, COVID-19 vaccination data, representing the number of people given at least one dose of vaccine, a list of the approved vaccination sites, population data and ancillary GIS data were used to assess vaccination coverage, using Kenya as an example. Firstly, physical access was modelled using travel time to estimate the proportion of population within 1 hour of a vaccination site. Secondly, a Bayesian conditional autoregressive (CAR) model was used to estimate the COVID-19 vaccination coverage and the same framework used to forecast coverage rates for the first quarter of 2022. Nationally, the average travel time to a designated COVID-19 vaccination site (n = 622) was 75.5 min (Range: 62.9 – 94.5 min) and over 87% of the population >18 years reside within 1 hour to a vaccination site. The COVID-19 vaccination coverage in December 2021 was 16.70% (95% CI: 16.66 – 16.74) – 4.4 million people and was forecasted to be 30.75% (95% CI: 25.04 – 36.96) – 8.1 million people by the end of March 2022. Approximately 21 million adults were still unvaccinated in December 2021 and, in the absence of accelerated vaccine uptake, over 17.2 million adults may not be vaccinated by end March 2022 nationally. Our results highlight geographic inequalities at sub-national level and are important in targeting and improving vaccination coverage in hard-to-reach populations. Similar mapping efforts could help other countries identify and increase vaccination coverage for such populations.  ",
keywords = "Bayesian conditional autoregressive, COVID-19, Spatial inequalities, Vaccination coverage",
author = "S.K. Muchiri and R. Muthee and H. Kiarie and J. Sitienei and A. Agweyu and P.M. Atkinson and {Edson Utazi}, C. and A.J. Tatem and V.A. Alegana",
year = "2022",
month = mar,
day = "18",
doi = "10.1016/j.vaccine.2022.02.035",
language = "English",
volume = "40",
pages = "2011--2019",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "13",

}

RIS

TY - JOUR

T1 - Unmet need for COVID-19 vaccination coverage in Kenya

AU - Muchiri, S.K.

AU - Muthee, R.

AU - Kiarie, H.

AU - Sitienei, J.

AU - Agweyu, A.

AU - Atkinson, P.M.

AU - Edson Utazi, C.

AU - Tatem, A.J.

AU - Alegana, V.A.

PY - 2022/3/18

Y1 - 2022/3/18

N2 - COVID-19 has impacted the health and livelihoods of billions of people since it emerged in 2019. Vaccination for COVID-19 is a critical intervention that is being rolled out globally to end the pandemic. Understanding the spatial inequalities in vaccination coverage and access to vaccination centres is important for planning this intervention nationally. Here, COVID-19 vaccination data, representing the number of people given at least one dose of vaccine, a list of the approved vaccination sites, population data and ancillary GIS data were used to assess vaccination coverage, using Kenya as an example. Firstly, physical access was modelled using travel time to estimate the proportion of population within 1 hour of a vaccination site. Secondly, a Bayesian conditional autoregressive (CAR) model was used to estimate the COVID-19 vaccination coverage and the same framework used to forecast coverage rates for the first quarter of 2022. Nationally, the average travel time to a designated COVID-19 vaccination site (n = 622) was 75.5 min (Range: 62.9 – 94.5 min) and over 87% of the population >18 years reside within 1 hour to a vaccination site. The COVID-19 vaccination coverage in December 2021 was 16.70% (95% CI: 16.66 – 16.74) – 4.4 million people and was forecasted to be 30.75% (95% CI: 25.04 – 36.96) – 8.1 million people by the end of March 2022. Approximately 21 million adults were still unvaccinated in December 2021 and, in the absence of accelerated vaccine uptake, over 17.2 million adults may not be vaccinated by end March 2022 nationally. Our results highlight geographic inequalities at sub-national level and are important in targeting and improving vaccination coverage in hard-to-reach populations. Similar mapping efforts could help other countries identify and increase vaccination coverage for such populations.  

AB - COVID-19 has impacted the health and livelihoods of billions of people since it emerged in 2019. Vaccination for COVID-19 is a critical intervention that is being rolled out globally to end the pandemic. Understanding the spatial inequalities in vaccination coverage and access to vaccination centres is important for planning this intervention nationally. Here, COVID-19 vaccination data, representing the number of people given at least one dose of vaccine, a list of the approved vaccination sites, population data and ancillary GIS data were used to assess vaccination coverage, using Kenya as an example. Firstly, physical access was modelled using travel time to estimate the proportion of population within 1 hour of a vaccination site. Secondly, a Bayesian conditional autoregressive (CAR) model was used to estimate the COVID-19 vaccination coverage and the same framework used to forecast coverage rates for the first quarter of 2022. Nationally, the average travel time to a designated COVID-19 vaccination site (n = 622) was 75.5 min (Range: 62.9 – 94.5 min) and over 87% of the population >18 years reside within 1 hour to a vaccination site. The COVID-19 vaccination coverage in December 2021 was 16.70% (95% CI: 16.66 – 16.74) – 4.4 million people and was forecasted to be 30.75% (95% CI: 25.04 – 36.96) – 8.1 million people by the end of March 2022. Approximately 21 million adults were still unvaccinated in December 2021 and, in the absence of accelerated vaccine uptake, over 17.2 million adults may not be vaccinated by end March 2022 nationally. Our results highlight geographic inequalities at sub-national level and are important in targeting and improving vaccination coverage in hard-to-reach populations. Similar mapping efforts could help other countries identify and increase vaccination coverage for such populations.  

KW - Bayesian conditional autoregressive

KW - COVID-19

KW - Spatial inequalities

KW - Vaccination coverage

U2 - 10.1016/j.vaccine.2022.02.035

DO - 10.1016/j.vaccine.2022.02.035

M3 - Journal article

VL - 40

SP - 2011

EP - 2019

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 13

ER -